To include your compound in the COVID-19 Resource Center, submit it here.

Panel unanimously backs boceprevir

FDA's Antiviral Drugs Advisory Committee voted 18-0 to recommend approval of boceprevir from Merck & Co. Inc. (NYSE:MRK) to treat HCV. The panel members

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE